Held in New Orleans during May 13–17, 2025, the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT 2025) showcased groundbreaking clinical advances in genetic medicine. The conference highlighted a range of innovations — from first-in-human gene therapies to novel delivery systems and immune-modulating cell treatments — emphasizing the accelerating pace of cell and gene therapy (CGT) research.
- Increasing the AAV-based Therapy Clinical Footprint
Key Development: With novel capsids, promoters, and regulating elements improving tissue specificity and safety, adeno-associated virus (AAV)-based gene therapies still rule the clinical pipeline.
Best Practices: Wilson disease’s copper-responsive AAV8 vector LY-M003 demonstrated encouraging safety and effectiveness, allowing patients to either stop or cut back on chelation therapy.
Growth Opportunities:
- Develop organ-specific capsids to lower off-target effects.
- Integrate dynamic expression systems (e.g., copper-responsive, RNAi-regulated) in AAV-based therapies.
- Extend AAV-based therapies to treat metabolic and neurodegenerative disorders.
- Exon Skipping and RNA Editing Reachthe Clinic
Key Development: Since RNA editing platforms provide reversible and safer therapeutic possibilities, they are being considered as suitable substitutes for DNA editing.
Best Practices: Early clinical evidence showed Exon 51 skipping, dystrophin restoration, and functional improvement in LE051 (phase I) – an AAV-delivery RNA editing treatment for Duchenne muscular dystrophy (DMD).
Growth Opportunities:
- Expand Exon skipping approaches to target a broader range of DMD variants.
- Develop delivery technologies for tissue-specific RNA editing to enhance precision and efficacy.
- Employ supportive therapies, such as physical therapy or corticosteroids along with Exon skipping to maximize clinical outcomes.
- Redefining Cell Therapy with Allogeneic CAR-T Approaches
Key Development: With immune evasion and persistence allowing off-the-shelf treatments, allogeneic chimeric antigen receptor T (CAR-T) platforms are fast evolving.
Best Practices: In B-cell non-Hodgkin lymphoma (B-NHL) patients, SPPL3-knockout CAR-T cells —engineered to retain T-cell receptors (TCRs) yet avoid graft-versus-host disease (GvHD) — demonstrated strong persistence and effective tumor control, confirming the viability of TCR-sufficient allogeneic CAR-T therapies.
Growth Opportunities:
- Expanding CAR-T therapies for autoimmune indications.
- Employing glycan shielding and TCR-sparing techniques help to lower GvHD.
- Developing scalable manufacturing platforms.
- Gene Therapy Gets Traction for Inherited Retinal Conditions
Key Development: Early clinical results of AAV-based therapies for hereditary retinal diseases show improvements in visual acuity and retinal structure.
Best Practices: In pediatric patients with X-linked retinoschisis, AAV2/8 gene therapy improved both visual acuity and retinal structure. Meanwhile, a gene-independent treatment for rod-cone dystrophy demonstrated early signs of efficacy and a favorable safety profile in a phase I/II trial.”
Growth Opportunities:
- Development of intravitreal distribution techniques for general use.
- Expansion of gene-agnostics and optogenetic techniques.
- Integration of gene therapy with digital vision evaluation technologies.
- Cardiac Gene Therapy Enters the Clinic
Key Development: Gene therapies targeting hereditary cardiomyopathies are advancing into early-phase clinical trials, showing promising safety profiles and encouraging biomarker responses.
Best Practices: AAVrh.74 vector delivering PKP2a demonstrated enhanced myocardial expression and no arrhythmia-related serious adverse events (SAEs) in patients with PKP2-associated arrhythmogenic cardiomyopathy.
Growth Opportunities:
- Developing heart-specific promoters and capsids.
- Implementing companion diagnostics for genetic screening.
- Employing long-term monitoring of cardiac function following therapy.
Looking ahead: At ASGCT 2025, the evolution of genetic medicine underscored the field’s commitment to safety, innovation, and fair access. Key areas of focus are:
- Short-term (1 year): Advancing RNA editing and AAV capsid engineering into more general conditions
- Mid-term (2–3 years): Scaling allogeneic CAR-T platforms and extending gene therapy into metabolic and neurodegenerative illnesses
- Long-term (5+ years): Attaining curative results by sustainable, precise gene and cell treatments with worldwide accessibility.
What’s your next move?
- Book a Growth Strategy Session – Align your CGT innovation roadmap with strategic insights to fast-track clinical translation and market impact.
- Engage with Growth Experts – Collaborate with our experts to identify high-potential opportunities across AAV, RNA editing, and allogeneic cell therapies.
- Tell Your Transformation Story – Highlight your breakthroughs in genetic medicine and inspire global stakeholders with your success.
- Join the Growth Council – Collaborate with pioneers driving the next wave of cell and gene therapy advancements.
- Explore New Growth Opportunities – Uncover emerging platforms and delivery technologies shaping the future of precision therapies.
Appendix:
Explore Frost & Sullivan’s latest analyses on CGT innovation and market dynamics:
